Navigation Links
China Yingxia International, Inc. Appoints Chief Financial Officer
Date:6/16/2008

HARBIN, China, June 16 /Xinhua-PRNewswire-FirstCall/ -- China Yingxia International, Inc. (OTC Bulletin Board: CYXI) ("China Yingxia" or "the Company"), a leading provider in the nutraceutical industry engaged in the development, manufacture and distribution of organic nutritional food products, supplements, and personal care products in the People's Republic of China ("PRC"), today announced the appointment of Mr. Ren Hu as its new chief financial officer effective June 11, 2008.

Mr. Hu assumed responsibility as the Company's CFO on June 11, 2008 and will report directly to Ms. Yingxia Jiao, CEO of China Yingxia. Mr. Hu will be responsible for overseeing the Company's overall financial planning, control and reporting activities, SEC compliance, audit and investor relations. Mr. Hu has over 25 years of experience in business and finance, with expertise on Wall Street. Prior to joining China Yingxia, Mr. Hu worked as a vice president of finance at China Kangtai Cactus Bio-Tech, Inc. (OTCBB: CKGT), from June 2006 to June 2008, where he was in charge of North American operations, namely timely filing of SEC reports, investor relations, and capital raising. In addition, Mr. Hu worked as the vice president for Phoenix Forest, LLC., the US investment banking arm of Lin Feng Group, in 2005, executing a reverse merger transaction for a China based power plant, and as the president for China Finance, Inc. (OTCBB: CHFI) in 2004, overseeing investor relations.

Mr. Hu also has extensive brokerage house and hedge fund management and trading experiences and has/had FINRA (formerly NASD) securities licenses S7, S55 and S63. Mr. Hu received his MBA from London Business School in 1989 and MS in finance from Florida International University in 1994. He is currently an ABD (all-but-dissertation doctoral candidate) in international business at Rutgers University.

"We are very pleased to have Mr. Hu join China Yingxia as our chief financial officer," said Ms.
'/>"/>

SOURCE China Yingxia International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. China Sky One Medical, Inc. to Acquire Peng Lai Jin Chuang Company
2. China Medical Technologies Reports Fourth Quarter and Full Year Financial Results
3. AmeriCares Establishes Field Hospital in China
4. China Sky One Medical, Inc. Announces Guidance for Second Quarter and Full Year 2008
5. AmeriCares Purchases BLU-MED Portable Hospital for China Earthquake Relief
6. Answers From Nature Introduces 100% Non-China Ingredients for Dietary Supplements
7. China Sky One Medical, Inc. Receives SFDA Approval for Five Patches
8. Meetings with Pre-Screened Verified China Suppliers Help 14 Top Buyers, Including Brookstone and Staples, Save Time and Cut Sourcing Costs
9. Free Wheelchair Mission to Distribute 4,400 Wheelchairs to China Earthquake Victims
10. China Nepstar Chain Drugstore Filed Its Annual Report on Form 20-F
11. China Sky One Medical, Inc. Donates RMB 1.1 Million in Medicine for Earthquake Disaster Relief Efforts
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3NASA Research Reveals Major Insight Into Evolution of Life on Earth 4870 1NASA Research Reveals Major Insight Into Evolution of Life on Earth 4870 2The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 1The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 2The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 3The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 4Patch Shots May Someday Replace Injections 54893 1Patch Shots May Someday Replace Injections 54893 2
Other Medicine Technology:New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 2New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 3New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 4New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 5New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 6SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 2SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 3SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 4SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 5SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 6SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 7